• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Filaggrin-2 (FLG2), Truncated

ACP17204

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP17204 Target NameFLG2
Target SynonymsFILA2_HUMAN; Filaggrin-2; FLG-2; FLG2; Ifapsoriasin; Intermediate filament-associated and psoriasis-susceptibility proteinFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ5D862
Background Information
  • Uniprot Id

    Q5D862

  • Target Species

    Human

  • Target Name

    FLG2

  • Target Full Name

    Filaggrin-2

  • Target Function

    Essential for normal cell-cell adhesion in the cornified cell layers. Important for proper integrity and mechanical strength of the stratum corneum of the epidermis.

  • Target Subcellular Location

    Cytoplasm. Cytoplasmic granule.

  • Target Protein Families

    S100-fused protein family; S-100 family

  • Target Tissue Specificity

    Expressed in skin, thymus, stomach and placenta, but not detected in heart, brain, liver, lung, bone marrow, small intestine, spleen, prostate, colon, adrenal gland, kidney, pancreas, mammary gland, bladder, thyroid, salivary gland and trachea. Weakly exp

  • Target Synonyms

    FILA2_HUMAN; Filaggrin-2; FLG-2; FLG2; Ifapsoriasin; Intermediate filament-associated and psoriasis-susceptibility protein

Inquire Recombinant Human Filaggrin-2 (FLG2), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification